Solu-Cortef Powder for Solution for Injection or Infusion 100 mg clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label, cross-over, multi-site, prospective, phase IIb study of effects on circadian rhythms and quality of life of modifieddual-release hydrocortisone Efmody™ versus immediate-release hydrocortisone in patients with Addison’s Disease
This study looks at how a new type of hydrocortisone, called Efmody™, compares to standard hydrocortisone for people with Addison's disease. Researchers want to see if Efmody™ improves daily life and body clocks better than current treatments. It's an important step to find the best ways to help people feel well.
For: Addison’s DiseaseIreland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
This study is testing a new cell therapy called ALLO-501A, along with another drug called ALLO-647, for adults with a type of blood cancer called Large B-Cell Lymphoma, where previous treatments haven't worked. It aims to see how safe and effective these new treatments are.
For: Large B-Cell Lymphoma (LBCL)Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy
This study is testing a new way to prepare people with a type of lymphoma (LBCL) for a special cell therapy called ALLO-501A. It compares two methods of preparing the body to see which works best and is safest.
For: Large B-Cell Lymphoma (LBCL)Belgium · Germany · Austria